AAGPs™ were invented by Dr. Geraldine-Castelot-Deliencourt and developed and protected by patents in partnership with the Institute for Scientific Application (INSA) of France. For her work in this area Dr. Castelot-Deliencourt was honored in 2006 with France’s highest award for scientific accomplishment – the Francinov Award.

ProtoKinetix owns the world-wide rights to a family of anti-aging glycoproteins, trademarked as AAGPs™.

In clinical tests AAGPs™ have demonstrated the ability to enhance the health and extend the life of biologically sensitive cells which have been subjected to severe stress conditions under laboratory controlled tests. AAGPs™ are stable and non-toxic.

Since inception in 2003, ProtoKinetix has primarily focused on scientific research, but the company is now in the process of directing major efforts to the practical side of commercialization. The commercial applications for AAGPs™ in large markets such as skincare/cosmetic products and targeted health care solutions are numerous, and ProtoKinetix is currently working with business leaders to bring AAGP™ to market.

Breakthrough advances in science have revolutionized skincare, cosmeceuticals, nutraceuticals and medicine. PKTX has been granted significant patent coverage that will permit it to apply the dynaminc interlocking molecular structure of AAGP™ to provide enhancement to a multitude of existing products, placing ProtoKinetix in an excellent position to be on the crest of this new tidal wave of opportunity as they turn science into business.

UMBILICAL CORD BLOOD INDUSTRY TEST PROTOKINETIX' AAGP
FEB 27, 2008

FORMER NAVY SURGEON GENERAL, ADMIRAL HAROLD M. KOENIG, M.D. JOINS PROTOKINETIX
MAY 14, 2008

JOHN S. PARKER. M.D., MAJOR GENERAL (Ret.) APPOINTED CHAIRMAN OF PROTOKINETIX' SCIENCE ADVISORY BOARD
MAY 06, 2008